FMS Kinase Inhibitors: Current Status and Future Prospects.

Autor: El-Gamal, Mohammed I., Anbar, Hanan S., Yoo, Kyung Ho, Oh, Chang-Hyun
Zdroj: Medicinal Research Reviews; Apr2013, Vol. 33 Issue 3, p599-636, 38p
Abstrakt: FMS, first discovered as the oncogene responsible for Feline Mc Donough Sarcoma, is a type III receptor tyrosine kinase that binds to the macrophage or monocyte colony-stimulating factor ( M- CSF or CSF-1). Signal transduction through that binding results in survival, proliferation, and differentiation of monocyte/macrophage lineage. Overexpression of CSF-1 and/or FMS has been implicated in a number of disease states such as the growth of metastasis of certain types of cancer, in promoting osteoclast proliferation in bone osteolysis, and many inflammatory disorders. Inhibition of CSF-1 and/or FMS may help treat these pathological conditions. This article reviews FMS gene, FMS kinase, CSF-1, IL-34, and their roles in bone osteolysis, cancer biology, and inflammation. Monoclonal antibodies, FMS crystal structure, and small molecule FMS kinase inhibitors of different chemical scaffolds are also reviewed. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index